A meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population.
BACKGROUND
Up to now, many publications about the Chinese population have evaluated the correlation between interleukin-10 (IL-10) -1082 and -592 polymorphisms and persistent hepatitis B virus (HBV) infection. However, the results remain inconclusive. In order to resolve this conflict, a meta-analysis was performed.


METHODS
Seven studies were included and dichotomous data are presented as the odds ratio (OR) with a 95% confidence interval (CI).


RESULTS
The results of our study suggest that carriers of the IL-10 -592A allele were more likely to clear HBV spontaneously in the Chinese pooled population (A vs. C: OR = 0.799, 95% CI = 0.678-0.941, P = 0.007; AC vs. AA: OR = 1.343, 95% CI = 1.017-1.684, P = 0.011; AA vs. AC + CC: OR = 0.736, 95% CI = 0.594-0.912; AA + AC vs. CC: OR = 0.588, 95% CI = 0.408-0.848, P = 0.004) and the IL-10 -1082A allele was associated with significantly reduced persistent HBV infection risk in Chinese (A vs. G: OR = 0.701, 95% CI = 0.494-0.996, P = 0.047; AA vs. GG + GA: OR = 0.684, 95% CI = 0.476-0.982, P = 0.040).


CONCLUSIONS
Persistent HBV infection susceptibility is associated with the gene polymorphism IL-10 -1082GA in the Chinese population and the clearance of HBV is associated with the gene polymorphism IL-10 -592CA in the Chinese population.
Department of Epidemiology and Biostatistics, Academy of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.
T-C
TC
Zhang
F-M
FM
Pan
L-Z
LZ
Zhang
Y-F
YF
Gao
Z-H
ZH
Zhang
J
J
Gao
R
R
Ge
Y
Y
Mei
B-B
BB
Shen
Z-H
ZH
Duan
X
X
Li
D002681:China; D020022:Genetic Predisposition to Disease; D006509:Hepatitis B / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D016753:Interleukin-10 / Q000235:genetics*; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic
D016753:Interleukin-10
Infect Genet Evol. 2008 Jan;8(1):20-5
17974504
Hepatol Res. 2006 Nov;36(3):158-66
16931134
Eur J Immunogenet. 1997 Feb;24(1):1-8
9043871
World J Gastroenterol. 2009 Nov 28;15(44):5610-9
19938203
Clin Chim Acta. 2010 Sep 6;411(17-18):1264-8
20488171
Liver Int. 2006 Apr;26(3):326-33
16584395
J Infect Dis. 2000 Nov;182(5):1545-8
11023480
J Med Virol. 2010 Mar;82(3):371-8
20087947
Anticancer Res. 1989 May-Jun;9(3):737-41
2764519
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8
8170985
Am J Gastroenterol. 2002 Aug;97(8):2086-92
12190181
J Neuroimmunol. 2000 Apr 3;104(1):98-100
10683520
Genes Immun. 1999 Nov;1(2):151-5
11196662
Arthritis Rheum. 1999 Jun;42(6):1101-8
10366102
J Infect Dis. 1999 Aug;180(2):496-9
10395868
World J Gastroenterol. 2003 Apr;9(4):641-4
12679901
J Viral Hepat. 2007 Dec;14(12):841-8
18070287
Tissue Antigens. 2006 Feb;67(2):127-33
16441483
Nat Med. 2006 Nov;12(11):1301-9
17041596
J Virol. 1994 Mar;68(3):1265-70
8107192
Am J Gastroenterol. 2003 Jan;98(1):144-50
12526950
Dig Dis Sci. 2010 Jul;55(7):1818-23
19777350
Immunity. 1996 Jan;4(1):25-36
8574849
Rev Gastroenterol Peru. 2009 Apr-Jun;29(2):147-57
19609330
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):410-4
16883528
J Viral Hepat. 2009 Nov;16(11):775-83
19413695
Hepatology. 1996 Jan;23(1):17-23
8550037
N Engl J Med. 1997 Dec 11;337(24):1733-45
9392700
Hepatology. 2000 Apr;31(4):828-33
10733535